Novo Nordisk A/S (NVO) vs Xenon Pharmaceuticals Inc. (XENE)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NVO | XENE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Biotechnology |
| Size band | LARGE | MID |
| Listing | NYSE | Nasdaq GM |
| Country | Denmark | Canada |
| Theme | glp-1-and-obesity | neuroscience |
| Price and returns | ||
| Last close | $39.13 | $35.34 |
| Return · 1 week | +1.85% | +0.74% |
| Return · 1 month | +1.08% | −3.76% |
| Return · 3 months | −23.21% | −45.58% |
| Return · year to date | −22.57% | −20.57% |
| Return · 1 year | −23.30% | −15.64% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −39.01% | −51.36% |
| 52-week high | $64.16 | $72.66 |
| 52-week low | $35.12 | $33.38 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $172.64B | $3.46B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $405.29M | $27.96M |
| Employees | 66,700 | 358 |
| Valuation | ||
| Price to earnings · trailing | 9.14× | — |
| Price to earnings · forward | 11.33× | — |
| Price to sales | 0.52× | — |
| Price to book | 5.19× | — |
| Enterprise value to EBITDA | 1.54× | — |
| Enterprise value to revenue | 0.81× | — |
| PEG ratio | 4.35 | — |
| Earnings per share · trailing | 4.25 | — |
| Profitability | ||
| Gross margin | 80.65% | — |
| Operating margin | 42.54% | — |
| Profit margin | 35.35% | — |
| Return on equity | 59.82% | — |
| Return on assets | 18.73% | — |
| Growth | ||
| Revenue growth | +2.10% | — |
| Earnings growth | −20.60% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 63.33 | — |
| Current ratio | 0.87 | — |
| Dividend yield | 4.63% | — |
| Payout ratio | 43.10% | — |
| Trend and volatility | ||
| RSI · 14 | 46.28 | 13.82 |
| ADX · 14 | 20.53 | 25.38 |
| 50-day average | $41.77 | $61.13 |
| 200-day average | $44.60 | $53.36 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 1.91% | 7.85% |
The full NVO analysis
Everything this table leaves out for Novo Nordisk A/S: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NVO argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NVO analysisThe full XENE analysis
Everything this table leaves out for Xenon Pharmaceuticals Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the XENE argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full XENE analysis